PMID- 37974915
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240430
IS  - 2474-1272 (Electronic)
IS  - 2474-1264 (Print)
IS  - 2474-1264 (Linking)
VI  - 7
IP  - 6
DP  - 2023 Nov-Dec
TI  - Clinical Outcome of Cystoid Macular Edema in Silicone Oil-Filled Eyes.
PG  - 477-482
LID - 10.1177/24741264231200739 [doi]
AB  - Purpose: To investigate the clinical outcome of cystoid macular edema (CME) in 
      eyes undergoing silicone oil (SO) tamponade with subsequent SO removal (SOR). 
      Methods: A retrospective case series of adult patients with CME treated with SO 
      tamponade and SOR was conducted between January 2015 and January 2021. Exclusion 
      criteria included eyes with a prior SO tamponade, those that did not undergo SOR, 
      or those with infectious/inflammatory diagnoses. The primary outcomes were the 
      incidence and resolution rates of CME in eyes with SO tamponade that had 
      undergone SOR. The secondary outcomes included changes in best-corrected visual 
      acuity (BCVA) and central field thickness (CFT). Results: Nineteen eyes of 19 
      patients (58% men) aged 52 years (interquartile range [IQR], 45-66 years) met the 
      study inclusion criteria. The median (IQR) follow-up duration post SOR was 22 
      (8-35) months. The mean CFT decline for the CME-resolved cases was 13.1 microm/mo 
      (P = .257). CME resolved in only 10 eyes (53%), 7 (67%) of which occurred after 
      SOR. The median (IQR) BCVA was 20/400 (20/200 to 20/1262) at CME diagnosis and 
      20/796 (20/252 to hand motions) after SOR, with 0.184 worsening in logMAR BCVA 
      (P = .340). Medical treatment was not associated with CME resolution compared 
      with observation (50% vs 89%, respectively; P = .069). Eyes with proliferative 
      vitreoretinopathy (PVR) had a higher rate of persistent CME compared with eyes 
      with other diagnoses (78% vs 10%, respectively; P = .005). Conclusions: Nearly 
      half had nonresolution of CME after SO was removed. The VA at the last follow-up 
      was unaffected by CME resolution. Preoperative PVR may be a risk factor for 
      unresolved CME.
CI  - (c) The Author(s) 2023.
FAU - Shaheen, Abdulla
AU  - Shaheen A
AUID- ORCID: 0000-0003-4448-2104
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Lai, James
AU  - Lai J
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Magraner, Maria
AU  - Magraner M
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Ashkenazy, Noy
AU  - Ashkenazy N
AD  - Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX, USA.
FAU - Flynn, Harry W Jr
AU  - Flynn HW Jr
AUID- ORCID: 0000-0002-9990-7467
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Sridhar, Jayanth
AU  - Sridhar J
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
FAU - Yannuzzi, Nicolas A
AU  - Yannuzzi NA
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of 
      Medicine, University of Miami, Miami, FL, USA.
LA  - eng
GR  - UL1 TR002736/TR/NCATS NIH HHS/United States
GR  - UM1 TR004556/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20230929
PL  - United States
TA  - J Vitreoretin Dis
JT  - Journal of vitreoretinal diseases
JID - 101700301
PMC - PMC10649453
OTO - NOTNLM
OT  - cystoid macular edema
OT  - pars plana vitrectomy
OT  - proliferative vitreoretinopathy
OT  - retinal detachment
OT  - silicone oil
OT  - visual acuity
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/11/17 15:30
MHDA- 2023/11/17 15:31
PMCR- 2024/09/29
CRDT- 2023/11/17 03:55
PHST- 2024/09/29 00:00 [pmc-release]
PHST- 2023/11/17 15:31 [medline]
PHST- 2023/11/17 15:30 [pubmed]
PHST- 2023/11/17 03:55 [entrez]
AID - 10.1177_24741264231200739 [pii]
AID - 10.1177/24741264231200739 [doi]
PST - epublish
SO  - J Vitreoretin Dis. 2023 Sep 29;7(6):477-482. doi: 10.1177/24741264231200739. 
      eCollection 2023 Nov-Dec.